【开放获取】 急危重皮肤病的诊疗原则、现状、挑战和展望

doi:10.35541/cjd.20240527

中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (4): 307-314.doi: 10.35541/cjd.20240527

• 专家论坛·急危重皮肤病 • 上一篇下一篇

【开放获取】急危重皮肤病的诊疗原则、现状、挑战和展望

何春霞晋红中

中国医学科学院北京协和医学院北京协和医院皮肤科疑难重症及罕见病国家重点实验室国家皮肤与免疫疾病临床医学研究中心，北京 100730

收稿日期:2024-10-08 修回日期:2025-02-21 发布日期:2025-04-03
通讯作者: 晋红中 E-mail:jinhongzhong@263.net
基金资助:
中央高水平医院临床科研业务费（2022-PUMCH-A-252、2022-PUMCH-B-092）；国家重点研发计划（2022YFC3601800）；国家临床重点专科建设项目；北京市临床重点专科建设项目；北京市自然科学基金（7242109）

Principles, current status, challenges and perspectives in the diagnosis and treatment of critical dermatological emergencies

He Chunxia, Jin Hongzhong

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China

Received:2024-10-08 Revised:2025-02-21 Published:2025-04-03
Contact: Jin Hongzhong E-mail:jinhongzhong@263.net
Supported by:
National High Level Hospital Clinical Research Funding （2022-PUMCH-A-252, 2022-PUMCH-B-092）; National Key R&D Program of China （2022YFC3601800）; National Key Clinical Specialty Project of China; Key Clinical Specialty Project of Beijing; Beijing Natural Science Foundation （7242109）

摘要/Abstract

摘要： 【摘要】急危重皮肤病一般指病情紧急、进展迅速、可能危及生命的皮肤疾病。本文系统阐述了急危重皮肤病的临床特征、诊断流程及治疗策略，包括重症药疹、重症自身免疫性大疱病和重症银屑病，强调早期识别、快速诊断、规范治疗和多学科协作在管理这类疾病中的重要性。此外，本文深入分析急危重皮肤病诊疗当前面临的挑战和风险，并从加强一级预防、完善转诊体系、规范诊疗流程等方面提出了具体改进措施，旨在为急危重皮肤病的规范化诊治提供实用的临床指导。

关键词: 危重病, 急危重皮肤病, 药疹, 皮肤疾病, 水疱大疱性, 泛发性脓疱型银屑病, 红皮病型银屑病, 多学科协作

Abstract: 【Abstract】 Critical dermatological emergencies generally refer to a group of dermatoses characterized by urgent onset, rapid progression, and potential life-threatening complications. This commentary elucidates the clinical characteristics of, diagnostic procedures, and therapeutic strategies for critical dermatological emergencies, including severe cutaneous adverse reactions, autoimmune bullous diseases, and psoriasis, emphasizing the importance of early recognition, diagnosis, standardized treatment, and multidisciplinary collaboration in their management. Furthermore, this commentary provides an in-depth analysis of the current challenges and risks in managing these conditions, and proposes specific improvement measures, such as strengthening primary prevention, optimizing referral systems, and standardizing diagnostic and therapeutic procedures, aiming to provide practical clinical guidance for the management of critical dermatological emergencies.

Key words: Critical illness, Critical dermatological emergencies, Drug eruptions, Skin diseases, vesiculobullous, Generalized pustular psoriasis, Erythrodermic psoriasis, Multidisciplinary management

何春霞晋红中. 【开放获取】 急危重皮肤病的诊疗原则、现状、挑战和展望[J]. 中华皮肤科杂志, 2025,58(4):307-314. doi:10.35541/cjd.20240527

He Chunxia, Jin Hongzhong . Principles, current status, challenges and perspectives in the diagnosis and treatment of critical dermatological emergencies[J]. Chinese Journal of Dermatology, 2025, 58(4): 307-314.doi:10.35541/cjd.20240527

参考文献 55

［1］	Billings SD. Common and critical inflammatory dermatoses every pathologist should know［J］. Mod Pathol, 2020,33（Suppl 1）:107⁃117. doi: 10.1038/s41379⁃019⁃0400⁃z.
［2］	Freiman A, Borsuk D, Sasseville D. Dermatologic emergencies［J］. CMAJ, 2005,173（11）:1317⁃1319. doi: 10.1503/cmaj.050783.
［3］	Bromley M, Marsh S, Layton A. Life⁃threatening skin conditions presenting to critical care［J］. BJA Educ, 2021,21（10）:376⁃383. doi: 10.1016/j.bjae.2021.05.007.
［4］	Yang JJ, Maloney NJ, Bach DQ, et al. Dermatology in the emergency department: prescriptions, rates of inpatient admission, and predictors of high utilization in the United States from 1996 to 2012［J］. J Am Acad Dermatol, 2021,84（5）:1480⁃1483. doi: 10.1016/j.jaad.2020.07.055.
［5］	Isnard C, Ingen⁃Housz⁃Oro S, Fardet L, et al. Dermatological emergencies: evolution from 2008 to 2014 and perspectives［J］. J Eur Acad Dermatol Venereol, 2017,31（2）:274⁃279. doi: 10. 1111/jdv.13860.
［6］	Cazzaniga S, Heidemeyer K, Zahn CA, et al. Dermatological emergencies and determinants of hospitalization in Switzerland: a retrospective study［J］. J Eur Acad Dermatol Venereol, 2024. doi: 10.1111/jdv.20176.
［7］	Bancalari⁃Díaz D, Gimeno⁃Mateos LI, Cañueto J, et al. Dermatologic emergencies in a tertiary hospital: a descriptive study［J］. Actas Dermosifiliogr, 2016,107（8）:666⁃673. doi: 10.1016/j.ad.2016.05.001.
［8］	Hung SI, Mockenhaupt M, Blumenthal KG, et al. Severe cutaneous adverse reactions［J］. Nat Rev Dis Primers, 2024,10（1）:30. doi: 10.1038/s41572⁃024⁃00514⁃0.
［9］	Wei BM, Fox LP, Kaffenberger BH, et al. Drug⁃induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis［J］. J Am Acad Dermatol, 2024,90（5）:885⁃908. doi: 10.1016/j.jaad.2023.02.072.
［10］	Egami S, Yamagami J, Amagai M. Autoimmune bullous skin diseases, pemphigus and pemphigoid［J］. J Allergy Clin Immunol, 2020,145（4）:1031⁃1047. doi: 10.1016/j.jaci.2020.02.013.
［11］	Powers CM, Thakker S, Gulati N, et al. Bullous pemphigoid: a practical approach to diagnosis and management in the modern era［J］. J Am Acad Dermatol, 2025:S0190⁃9622（25）00185⁃00189 ［pii］. doi: 10.1016/j.jaad.2025.01.086.
［12］	Schmidt E, Kasperkiewicz M, Joly P. Pemphigus［J］. Lancet, 2019,394（10201）:882⁃894. doi: 10.1016/S0140⁃6736（19）31778⁃7.
［13］	Armstrong AW, Elston CA, Elewski BE, et al. Generalized pustular psoriasis: a consensus statement from the National Psoriasis Foundation［J］. J Am Acad Dermatol, 2024,90（4）:727⁃730. doi: 10.1016/j.jaad.2023.09.080.
［14］	Shao S, Wang G, Maverakis E, et al. Targeted treatment for erythrodermic psoriasis: rationale and recent advances［J］. Drugs, 2020,80（6）:525⁃534. doi: 10.1007/s40265⁃020⁃01283⁃2.
［15］	Prinz JC, Choon SE, Griffiths C, et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: a literature review［J］. J Eur Acad Dermatol Venereol, 2023,37（2）:256⁃273. doi: 10.1111/jdv.18720.
［16］	Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients［J］. J Am Acad Dermatol, 1989,21（5 Pt 1）:985⁃991.
［17］	Creamer D, Walsh SA, Dziewulski P, et al. U.K. guidelines for the management of Stevens⁃Johnson syndrome/toxic epidermal necrolysis in adults 2016［J］. Br J Dermatol, 2016,174（6）:1194⁃1227. doi: 10.1111/bjd.14530.
［18］	Brüggen MC, Walsh S, Ameri MM, et al. Management of adult patients with drug reaction with eosinophilia and systemic symptoms: a delphi⁃based international consensus［J］. JAMA Dermatol, 2024,160（1）:37⁃44. doi: 10.1001/jamadermatol.2023. 4450.
［19］	Tetart F, Walsh S, Milpied B, et al. Acute generalized exanthematous pustulosis: European expert consensus for diagnosis and management［J］. J Eur Acad Dermatol Venereol, 2024,38（11）:2073⁃2081. doi: 10.1111/jdv.20232.
［20］	《脓疱型银屑病诊疗中国专家共识（2022版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）［J］. 中华皮肤科杂志, 2022,55（3）:187⁃195. doi: 10.35541/cjd.20210698.
［21］	Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens⁃Johnson Syndrome and toxic epidermal necrolysis: comparison with case⁃control analysis［J］. Clin Pharmacol Ther, 2010,88（1）:60⁃68. doi: 10.1038/clpt.2009.252.
［22］	中华医学会皮肤性病学分会药物不良反应研究中心. Stevens⁃Johnson综合征/中毒性表皮坏死松解症诊疗专家共识［J］. 中华皮肤科杂志, 2021,54（5）:376⁃381. doi: 10.35541/cjd.2020 1177.
［23］	Huang S, Anderson HJ, Lee JB. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome: PartⅡ. Diagnosis and management［J］. J Am Acad Dermatol, 2024,91（1）:13⁃22. doi: 10.1016/j.jaad.2023.08.084.
［24］	中国医师协会皮肤科医师分会, 中华医学会皮肤性病学分会治疗学组, 中国医疗保健国际交流促进会皮肤医学分会, 等. 中国天疱疮诊疗指南（2024版）［J］. 中华皮肤科杂志, 2024,57（10）:873⁃886. doi: 10.35541/cjd.20240222.
［25］	中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）［J］. 中华皮肤科杂志, 2024,57（5）:409⁃417. doi: 10.35541/cjd.2023 0570.
［26］	Bastuji⁃Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity⁃of⁃illness score for toxic epidermal necrolysis［J］. J Invest Dermatol, 2000,115（2）:149⁃153. doi: 10.1046/j.1523⁃1747.2000.00061.x.
［27］	Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF⁃α antagonist in CTL⁃mediated severe cutaneous adverse reactions［J］. J Clin Invest, 2018,128（3）:985⁃996. doi: 10.1172/JCI93349.
［28］	Olsson⁃Brown A, Yip V, Ogiji ED, et al. TNF⁃α⁃mediated keratinocyte expression and release of matrix metalloproteinase 9: putative mechanism of pathogenesis in Stevens⁃Johnson syndrome/toxic epidermal necrolysis［J］. J Invest Dermatol, 2023,143（6）:1023⁃1030.e7. doi: 10.1016/j.jid.2022.11.024.
［29］	Nordmann TM, Anderton H, Hasegawa A, et al. Spatial proteomics identifies JAKi as treatment for a lethal skin disease［J］. Nature, 2024,635（8040）:1001⁃1009. doi: 10.1038/s41586⁃024⁃08061⁃0.
［30］	Gibson A, Ram R, Gangula R, et al. Multiomic single⁃cell sequencing defines tissue⁃specific responses in Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J］. Nat Commun, 2024,15（1）:8722. doi: 10.1038/s41467⁃024⁃52990⁃3.
［31］	Yang L, Shou YH, Li F, et al. Retrospective study of 213 cases of Stevens⁃Johnson syndrome and toxic epidermal necrolysis from China［J］. Burns, 2020,46（4）:959⁃969. doi: 10.1016/j.burns.2019.10.008.
［32］	Brauchle M, Fässler R, Werner S. Suppression of keratinocyte growth factor expression by glucocorticoids in vitro and during wound healing［J］. J Invest Dermatol, 1995,105（4）:579⁃584. doi: 10.1111/1523⁃1747.ep12323521.
［33］	Wei BM, Fox LP, Kaffenberger BH, et al. Drug⁃induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. PartⅡ diagnosis and management［J］. J Am Acad Dermatol, 2024,90（5）:911⁃926. doi: 10.1016/j.jaad.2023. 02.073.
［34］	Kim D, Kobayashi T, Voisin B, et al. Targeted therapy guided by single⁃cell transcriptomic analysis in drug⁃induced hypersensitivity syndrome: a case report［J］. Nat Med, 2020,26（2）:236⁃243. doi: 10.1038/s41591⁃019⁃0733⁃7.
［35］	Parisi R, Shah H, Navarini AA, et al. Acute generalized exanthematous pustulosis: clinical features, differential diagnosis, and management［J］. Am J Clin Dermatol, 2023,24（4）:557⁃575. doi: 10.1007/s40257⁃023⁃00779⁃3.
［36］	Xuan Y, Jin S, Zhang C, et al. Rapid improvement in refractory acute generalized exanthematous pustulosis with spesolimab［J］. JAMA Dermatol, 2024,160（9）:1009⁃1012. doi: 10.1001/jamadermatol.2024.2311.
［37］	Rahbar Z, Daneshpazhooh M, Mirshams⁃Shahshahani M, et al. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score［J］. JAMA Dermatol, 2014,150（3）:266⁃272. doi: 10.1001/jamadermatol.2013.8175.
［38］	Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts［J］. J Am Acad Dermatol, 2012,66（3）:479⁃485. doi: 10.1016/j.jaad.2011.06.032.
［39］	Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology （EADV）［J］. J Eur Acad Dermatol Venereol, 2020,34（9）:1900⁃1913. doi: 10.1111/jdv.16752.
［40］	Lee MS, Yeh YC, Tu YK, et al. Network meta⁃analysis⁃based comparison of first⁃line steroid⁃sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus［J］. J Am Acad Dermatol, 2021,85（1）:176⁃186. doi: 10.1016/j.jaad. 2020.08.028.
［41］	Antiga E, Bech R, Maglie R, et al. S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology （EADV）［J］. J Eur Acad Dermatol Venereol, 2023,37（6）:1118⁃1134. doi: 10.1111/jdv.18931.
［42］	Anderson HJ, Huang S, Lee JB. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome: Part I. Clinical overview and pathophysiology［J］. J Am Acad Dermatol, 2024,91（1）:1⁃10. doi: 10.1016/j.jaad.2023.08.020.
［43］	Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology （EADV）［J］. J Eur Acad Dermatol Venereol, 2022,36（10）:1689⁃1704. doi: 10.1111/jdv.18220.
［44］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会. 自身免疫性表皮下大疱病诊疗共识（2022）［J］. 中华皮肤科杂志, 2022,55（1）:1⁃11. doi: 10.35541/cjd.20210532.
［45］	Zhao L, Wang Q, Liang G, et al. Evaluation of dupilumab in patients with bullous pemphigoid［J］. JAMA Dermatol, 2023,159（9）:953⁃960. doi: 10.1001/jamadermatol.2023.2428.
［46］	Chebani R, Lombart F, Chaby G, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first⁃line therapy: a French national multicentre retrospective study of 100 patients［J］. Br J Dermatol, 2024,190（2）:258⁃265. doi: 10.1093/bjd/ljad369.
［47］	Karakioulaki M, Eyerich K, Patsatsi A. Advancements in bullous pemphigoid treatment: a comprehensive pipeline update［J］. Am J Clin Dermatol, 2024,25（2）:195⁃212. doi: 10.1007/s40257⁃023⁃00832⁃1.
［48］	Chaudhary NS, Donnelly JP, Moore JX, et al. Association of baseline steroid use with long⁃term rates of infection and sepsis in the REGARDS cohort［J］. Crit Care, 2017,21（1）:185. doi: 10.1186/s13054⁃017⁃1767⁃1.
［49］	Rygård SL, Butler E, Granholm A, et al. Low⁃dose corticosteroids for adult patients with septic shock: a systematic review with meta⁃analysis and trial sequential analysis［J］. Intensive Care Med, 2018,44（7）:1003⁃1016. doi: 10.1007/s00134⁃018⁃5197⁃6.
［50］	Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021［J］. Intensive Care Med, 2021,47（11）:1181⁃1247. doi: 10.1007/s00134⁃021⁃06506⁃y.
［51］	Malpica L, Moll S. Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases［J］. Hematology Am Soc Hematol Educ Program, 2020,2020（1）:319⁃327. doi: 10.1182/hematology.2020000116.
［52］	Rumancik B, Keele BJ, Rahnama⁃Moghadam S. Characterization of medical malpractice lawsuits relating to dermatologic emergencies in the inpatient and emergency settings［J］. J Am Acad Dermatol, 2022,86（2）:445⁃446. doi: 10.1016/j.jaad.2020. 02.015.
［53］	Zheng ZQ, Jiang C, Yu RL, et al. General characteristics, economic burden, causative drugs and medical errors associated with medical damage litigation involving severe cutaneous adverse drug reactions in China［J］. J Clin Pharm Ther, 2020,45（5）:1087⁃1097. doi: 10.1111/jcpt.13174.
［54］	Marsch A, Khodosh R, Porter M, et al. Implementing patient safety and quality improvement in dermatology. Part 1: patient safety science［J］. J Am Acad Dermatol, 2023,89（4）:641⁃654. doi: 10.1016/j.jaad.2022.01.049.
［55］	Jantararoungtong T, Tempark T, Koomdee N, et al. Genotyping HLA alleles to predict the development of Severe cutaneous adverse drug reactions （SCARs）: state⁃of⁃the⁃art［J］. Expert Opin Drug Metab Toxicol, 2021,17（9）:1049⁃1064. doi: 10.1080/17425255.2021.1946514.

[1]	包诗杰韩梅周小勇. 基于文献回顾的依那西普治疗中毒性表皮坏死松解症疗效影响因素分析[J]. 中华皮肤科杂志, 2025, 58(4): 352-355.
[2]	王思凡何春霞晋红中. 【开放获取】药物超敏反应综合征继发肺孢子菌肺炎的临床特征和影响因素探索[J]. 中华皮肤科杂志, 2025, 58(4): 315-321.
[3]	董艺穆妮热·塔伊尔闫昕章星琪. 机器学习在皮肤疾病中的研究应用[J]. 中华皮肤科杂志, 2025, 0(3): 20240290-e20240290.
[4]	魏亚鹿沈征宇. 空间转录组学及其在皮肤疾病中的应用[J]. 中华皮肤科杂志, 2025, 0(3): 20220429-e20220429.
[5]	陈良宏孙艳王敬玉吴严. 本维莫德在皮肤病中的研究进展[J]. 中华皮肤科杂志, 2025, 58(3): 266-268.
[6]	中国康复医学会皮肤病康复专业委员会中华医学会皮肤性病学分会中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组. [开放获取] 红蓝黄光治疗皮肤病临床应用专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(3): 209-215.
[7]	中国医学装备协会皮肤病与皮肤美容分会. 皮肤病靶向治疗专家共识（2025版） [J]. 中华皮肤科杂志, 2025, 58(2): 99-125.
[8]	艾芳婷孙紫君苗国英姚春霞. 钙敏感受体在老年皮肤病理生理中的作用研究进展[J]. 中华皮肤科杂志, 2025, 58(1): 76-79.
[9]	张嘉琪吴凡韩雨晴刘琦盘瑶. 多光子显微镜在皮肤科中的应用[J]. 中华皮肤科杂志, 2024, 57(9): 857-862.
[10]	郝峰刘国艳. [开放获取] 光学相干断层扫描技术在皮肤科的应用进展[J]. 中华皮肤科杂志, 2024, 57(9): 853-857.
[11]	邹先彪陈锦纯曾悦郝轶. [开放获取] 超声检查在皮肤科的应用前景[J]. 中华皮肤科杂志, 2024, 57(9): 785-790.
[12]	曾悦邵惠红林诗雯温柔邹先彪. 可穿戴远程会诊设备在常见皮肤病诊断中的应用[J]. 中华皮肤科杂志, 2024, 57(9): 797-800.
[13]	荆可李锁冯素英. 线状IgA大疱性皮病26例临床及免疫血清学特征回顾分析[J]. 中华皮肤科杂志, 2024, 57(6): 503-509.
[14]	韩燕徐鹏向志姜婷婷葛凤琴尹跃平陈祥生. [开放获取] 加强慢性皮肤病的防治研究——群医学研究计划[J]. 中华皮肤科杂志, 2024, 57(6): 567-569.
[15]	王晨薛晨红宋静卉李建国李振鲁张守民李明王建波. 阿达木单抗治疗Blau综合征1家系3例[J]. 中华皮肤科杂志, 2024, 57(6): 553-556.

【开放获取】急危重皮肤病的诊疗原则、现状、挑战和展望

Principles, current status, challenges and perspectives in the diagnosis and treatment of critical dermatological emergencies

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 55

相关文章 15

Metrics

本文评价

推荐阅读 10

【开放获取】 急危重皮肤病的诊疗原则、现状、挑战和展望

Principles, current status, challenges and perspectives in the diagnosis and treatment of critical dermatological emergencies

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 55

相关文章 15

Metrics

本文评价

推荐阅读 10

【开放获取】急危重皮肤病的诊疗原则、现状、挑战和展望